To further investigate the underlying causes and mechanisms of this excellent response to combined anti-CTLA-4 and anti-PD-L1 blockade after progression under single agent PD-1 inhibiting therapy, we performed a molecular pathological analysis of the tumor tissue. This evidence concerns the gene PDCD1 and neoplasm.